Structure–Activity Relationship Studies of 9-Alkylamino-1,2,3,4-tetrahydroacridines against Leishmania (Leishmania) infantum Promastigotes
Authors:
Open Access
- 16 February 2023
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (2) , 669
Abstract
Leishmaniasis is one of the most neglected diseases in modern times, mainly affecting people from developing countries of the tropics, subtropics and the Mediterranean basin, with approximately 350 million people considered at risk of developing this disease. The incidence of human leishmaniasis has increased over the past decades due to failing prevention and therapeutic measures—there are no vaccines and chemotherapy, which is problematic. Acridine derivatives constitute an interesting group of nitrogen-containing heterocyclic compounds associated with numerous bioactivities, with emphasis to their antileishmanial potential. The present work builds on computational studies focusing on a specific enzyme of the parasite, S-adenosylmethionine decarboxylase (AdoMet DC), with several 1,2,3,4-tetrahydro-acridines emerging as potential inhibitors, evidencing this scaffold as a promising building block for novel antileishmanial pharmaceuticals. Thus, several 1,2,3,4-tetrahydroacridine derivatives have been synthesized, their activity against Leishmania (Leishmania) infantum promastigotes evaluated and a structure–activity relationship (SAR) study was developed based on the results obtained. Even though the majority of the 1,2,3,4-tetrahydroacridines evaluated presented high levels of toxicity, the structural information gathered in this work allowed its application with another scaffold (quinoline), leading to the obtention of N1,N12-bis(7-chloroquinolin-4-yl)dodecane-1,12-diamine (12) as a promising novel antileishmanial agent (IC50 = 0.60 ± 0.11 μM, EC50 = 11.69 ± 3.96 μM and TI = 19.48).Keywords
Funding Information
- Fundação para a Ciência e Tecnologia (FCT UIDB/50006/2020, UIDB/04293/2020, PD/BD/135103/2017, COVID/BD/151838/2021, 2020.05346.BD, SFRH/BD/148426/2019)
- Fundação para a Ciência e a Tecnologia (FCT UIDB/50006/2020, UIDB/04293/2020, PD/BD/135103/2017, COVID/BD/151838/2021, 2020.05346.BD, SFRH/BD/148426/2019)
- Fundação para a Ciência e a Tecnologia (FCT UIDB/50006/2020, UIDB/04293/2020, PD/BD/135103/2017, COVID/BD/151838/2021, 2020.05346.BD, SFRH/BD/148426/2019)
This publication has 17 references indexed in Scilit:
- LeishmaniasisJournal of Infection, 2014
- Acridine and its derivatives: a patent review (2009 – 2013)Expert Opinion on Therapeutic Patents, 2014
- Antileishmanial Natural Products from Plants2012
- Plant derived therapeutics for the treatment of LeishmaniasisPhytomedicine, 2011
- Parallel Synthesis, Evaluation, and Preliminary Structure−Activity Relationship of 2,5-Diamino-1,4-benzoquinones as a Novel Class of Bivalent Anti-Prion CompoundJournal of Medicinal Chemistry, 2010
- Drug targets in LeishmaniaJournal of Parasitic Diseases, 2010
- Cross-species activation of trypanosome S-adenosylmethionine decarboxylase by the regulatory subunit prozymeMolecular and Biochemical Parasitology, 2009
- Targeting the polyamine biosynthetic enzymes: a promising approach to therapy of African sleeping sickness, Chagas’ disease, and leishmaniasisAmino Acids, 2007
- Allosteric regulation of an essential trypanosome polyamine biosynthetic enzyme by a catalytically dead homologProceedings of the National Academy of Sciences, 2007
- Homodimeric Tacrine Congeners as Acetylcholinesterase InhibitorsJournal of Medicinal Chemistry, 2002